Name: ABSA’s 1st Biosecurity Symposium
Start: 2021-04-20T00:00:00-05:00
End: 2021-04-23T23:59:59-05:00
Location: Renaissance Depot Hotel

Novel Inhaled Vaccine for Tuberculosis Shows Strong Immune Response in Mice

Stopping Lethal Lung Damage from Influenza: MG53 Protein Shows Promise in Animal Models

by Global Biodefense Staff October 13, 2020, 1:35 pm
Scientists Engineer Bacteria-Killing Molecules from Wasp Venom

by Global Biodefense Staff October 13, 2020, 12:17 pm
NIH Funds a $9.3M Center for Precision Animal Modeling at UAB

by Global Biodefense Staff October 9, 2020, 12:09 pm
Pipeline COVID-19 Vaccines Not Affected by ‘G-Strain’ Mutation

by Global Biodefense Staff October 8, 2020, 7:01 am
Renowned Tick Immunobiologist to Develop Lyme Disease Vaccine Under New $3.5M Federal Grant

by Global Biodefense Staff October 7, 2020, 9:48 am
Why It Matters That the U.S. Is Not Supporting COVAX

by Nicole Hassoun October 3, 2020, 3:03 pm
HHS Pushes Out COVID-19 Mass Vaccination Playbook, Distribution Strategy

by Global Biodefense Staff September 16, 2020, 10:15 am
The Big 3 Infectious Diseases Besides COVID-19 Scientists Are Trying to Find a Vaccine For

by Danielle Stanisic and Johnson Mak September 14, 2020, 11:20 am
COVID-19 Industry Rivals Plan Joint Pledge on Vaccine Safety

by Global Biodefense Staff September 4, 2020, 3:39 pm
Lessons From Hydroxychloroquine: Improving FDA’s Authorization and Approval Process

by Global Biodefense Staff August 31, 2020, 3:20 pm
Newsletter

Global Biodefense News

First Name

Last Name

Organization Type

Email address:

Don't worry, we don't spam
USAMRIID Scientists Engineer First Lethal Mouse Model for COVID-19

by Global Biodefense Staff August 27, 2020, 9:30 am
Vaccine Approval Is Just The Beginning – Huge Production Challenges Await

by Bruce Y. Lee, CUNY August 24, 2020, 6:48 am
UC Riverside Scientists Use AI to Drive COVID Countermeasure Discovery

by Global Biodefense Staff August 12, 2020, 8:01 am
Urgent Phase I/II Clinical Trial Funding to Repurpose Existing Therapeutics to Treat COVID-19

by Global Biodefense Staff August 6, 2020, 1:18 pm

Congratulations. You've reached the end of the internet.

Drug Development

Novel Inhaled Vaccine for Tuberculosis Shows Strong Immune Response in Mice

Artificial Intelligence Collaboration Seeking to Hasten COVID-19 Insights

Altimmune Poised to Begin Phase 1 Clinical Trial of Single-Dose Intranasal COVID-19 Vaccine

NIAID Looks Ahead to Pan-Coronavirus Vaccine Candidates

Stopping Lethal Lung Damage from Influenza: MG53 Protein Shows Promise in Animal Models

Scientists Engineer Bacteria-Killing Molecules from Wasp Venom

NIH Funds a $9.3M Center for Precision Animal Modeling at UAB

Pipeline COVID-19 Vaccines Not Affected by ‘G-Strain’ Mutation

Renowned Tick Immunobiologist to Develop Lyme Disease Vaccine Under New $3.5M Federal Grant

Why It Matters That the U.S. Is Not Supporting COVAX

HHS Pushes Out COVID-19 Mass Vaccination Playbook, Distribution Strategy

The Big 3 Infectious Diseases Besides COVID-19 Scientists Are Trying to Find a Vaccine For

COVID-19 Industry Rivals Plan Joint Pledge on Vaccine Safety

Lessons From Hydroxychloroquine: Improving FDA’s Authorization and Approval Process

USAMRIID Scientists Engineer First Lethal Mouse Model for COVID-19

Vaccine Approval Is Just The Beginning – Huge Production Challenges Await

UC Riverside Scientists Use AI to Drive COVID Countermeasure Discovery

Urgent Phase I/II Clinical Trial Funding to Repurpose Existing Therapeutics to Treat COVID-19

Biodefense Headlines – 21 January 2021

First Cases of B.1.1.7 Variant COVID-19 Detected in Washington State

The Response Measures Database: Central Archive of COVID-19 Interventions

EU Initiative on Health Security Work Programme 2021

Rapid Identification of Ricin in Serum Samples Using LC–MS/MS

Dr. Fauci Makes First Appearance at Biden White House Press Briefing – Transcript

ASM Expresses Support for the Global Health Security Act of 2021

How and When Will Lower-Income Countries Gain Access to COVID-19 Vaccines?

OHDSI Awarded $10M FDA Contract to Monitor Safety and Effectiveness of Vaccines, Biologics

Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity

NIAID Looks Ahead to Pan-Coronavirus Vaccine Candidates

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats

Emerging Infections Network – Managing Travelers Who Acquire Disease Abroad

Upcoming Events

Application Deadline: Expanding Existing Research Grants, CRADAs for Novel Coronavirus Response

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 2

Systematizing the One Health Approach in Preparedness and Response Efforts for Infectious Disease Outbreaks

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 3

ABSA’s 1st Biosecurity Symposium

Latest stories

Latest Articles